Aptevo Therapeutics Inc. (APVO) Stock Forecast
APVO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $25.50 average of analyst targets
- Upside to target
- +1,474.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-3.72
- 52-week range
- $1.62 – $29.16
APVO analyst ratings
1 analystsNumber of analysts at each rating.
APVO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
APVO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.54 | −$3.54 | −$3.54 | −$40.14 | +91.2% | 1 |
| Current fiscal year (2026) | −$16.02 | −$16.02 | −$16.02 | −$87.27 | +81.6% | 1 |
| Next fiscal year (2027) | −$10.40 | −$10.40 | −$10.40 | −$16.02 | +35.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
APVO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
APVO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
APVO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$5.96 | −$5.96 | −$5.96 | −$3.54 | −$3.54 | −40.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$24.13 | −$24.13 | −$24.13 | −$16.02 | −$16.02 | −33.6% | 0 up · 1 down |
| Next fiscal year (2027) | −$21.46 | −$21.46 | −$21.46 | −$10.40 | −$10.40 | −51.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
APVO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; APVO beat in 8 of 12.
What analysts expect from APVO
1 analysts cover Aptevo Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.50, 1,474.1% above the latest close of $1.62. Analysts expect earnings of −$16.02 per share for 2026, +81.6% from a year earlier. For 2027 the average estimate is −$10.40 per share. Aptevo Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: APVO income statement, APVO key metrics, APVO chart. See the APVO stock overview for the latest quote and news.
APVO forecast FAQ
What is Aptevo Therapeutics's price target?
The average analyst price target for Aptevo Therapeutics is $25.50, 1,474.1% above the latest close of $1.62.
Is Aptevo Therapeutics a buy, hold or sell?
Of 1 analysts covering Aptevo Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aptevo Therapeutics's EPS forecast?
Analysts forecast −$16.02 per share for 2026 (range −$16.02 to −$16.02); for 2027 the estimate is −$10.40.
When does Aptevo Therapeutics report earnings?
Aptevo Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-3.72.
Does Aptevo Therapeutics usually beat earnings estimates?
Aptevo Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.